Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 6

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 6
---
. “Legacy CERo” refers to CERo Therapeutics,
Inc. prior to the consummation of the Business Combination.

<div align='center'>ii

MARKET AND INDUSTRY INFORMATION</div>

Certain information contained
in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and our own
internal estimates and research. We believe these third-party sources to be reliable as of the date of this prospectus and we are responsible
for such information. Such information and data involves risks and uncertainties and is subject to change based on various factors, including,
potentially, those discussed under the section of this prospectus entitled “Risk Factors.” Furthermore, such information
and data cannot always be verified with complete certainty due to limits on the availability and reliability of raw data, the voluntary
nature of the data gathering process and other limitations and uncertainties inherent in any statistical survey. Additionally, while
our own internal research has not been verified by any independent source, we believe such research to be reliable and are responsible
for any information disclosed in this prospectus based upon such internal research.

<div align='center'>iii

TRADEMARKS</div>

This document contains references
to trademarks and service marks belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus
may appear without the ® or ™ symbols, but such references are not intended to indicate, in any way, that the applicable licensor
will not assert, to the fullest extent under applicable law, its rights to these trademarks and trade names. We do not intend our use
or display of other companies’ trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship
of us by, any other companies.

<div align='center'>iv

SELECTED DEFINITIONS</div>

As used in this prospectus,
unless otherwise noted or the context otherwise requires, references to the following capitalized terms have the meanings set forth below:

“Arena”
refers to Arena Business Solutions Global SPC II, Ltd. on behalf of and for the account of Segregated Portfolio #13 – SPC #13.

“Arena Commitment Shares” refer to up to 3,456 shares of Common Stock issued to Arena as consideration for executing and delivering the Arena
Purchase Agreement.

“Arena Equity Financing”
refers to the equity line of credit established by the Arena Purchase Agreement.

“Arena Purchase Agreement” refers to the Purchase Agreement, dated as of